company background image

Ascendis HealthJSE:ASC Stock Report

Market Cap







25 Oct, 2021


Company Financials
ASC fundamental analysis
Snowflake Score
Future Growth0/6
Past Performance0/6
Financial Health3/6

ASC Overview

Ascendis Health Limited, a health and wellness company, manufactures and distributes healthcare products in South Africa, Cyprus, Spain, Hungary, Romania, and internationally.

Price History & Performance

Summary of all time highs, changes and price drops for Ascendis Health
Historical stock prices
Current Share PriceR1.06
52 Week HighR0.43
52 Week LowR1.30
1 Month Change89.29%
3 Month Change76.67%
1 Year Change76.67%
3 Year Change-86.63%
5 Year Change-96.10%
Change since IPO-90.45%

Recent News & Updates

Shareholder Returns

ASCZA PharmaceuticalsZA Market

Return vs Industry: ASC underperformed the ZA Pharmaceuticals industry which returned 85.9% over the past year.

Return vs Market: ASC exceeded the ZA Market which returned 19% over the past year.

Price Volatility

Is ASC's price volatile compared to industry and market?
ASC volatility
ASC Beta0.67
Industry Beta0.56
Market Beta1

Stable Share Price: ASC is more volatile than 75% of ZA stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: ASC's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of ZA stocks.

About the Company

2008n/aMark James Van Sardi

Ascendis Health Limited, a health and wellness company, manufactures and distributes healthcare products in South Africa, Cyprus, Spain, Hungary, Romania, and internationally. The company operates through Consumer Health, Pharma, and Medical segments. It offers body and skin products; and natural supplements, multi-vitamin and mineral supplements, micronutrient supplements, nutraceutical supplements, vitamins, minerals, and homeopathic and herbal products under the Bettaway, Chela-Fer, Chela Mag, Compounding Pharmacy, Junglevites, Menacal 7, Nimue, Scitec, Solal, and Vitaforce brand names.

Ascendis Health Fundamentals Summary

Earnings & Revenue

Key profitability statistics from the latest earnings report
ASC income statement (TTM)
Cost of RevenueR1.30b
Gross ProfitR930.68m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date


Earnings per share (EPS)-3.42
Gross Margin41.75%
Net Profit Margin-74.11%
Debt/Equity Ratio1,322.1%

How did ASC perform over the long term?

See historical performance and comparison


Is Ascendis Health undervalued compared to its fair value and its price relative to the market?


Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: ASC (ZAR1.06) is trading below our estimate of fair value (ZAR43.55)

Significantly Below Fair Value: ASC is trading below fair value by more than 20%.

Price To Earnings Ratio

PE vs Industry: ASC is unprofitable, so we can't compare its PE Ratio to the African Pharmaceuticals industry average.

PE vs Market: ASC is unprofitable, so we can't compare its PE Ratio to the ZA market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ASC's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: ASC is good value based on its PB Ratio (1.5x) compared to the XF Pharmaceuticals industry average (2x).

Future Growth

How is Ascendis Health forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?


Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Ascendis Health has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Past Performance

How has Ascendis Health performed over the past 5 years?


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: ASC is currently unprofitable.

Growing Profit Margin: ASC is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: ASC is unprofitable, and losses have increased over the past 5 years at a rate of 55.5% per year.

Accelerating Growth: Unable to compare ASC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ASC is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (10%).

Return on Equity

High ROE: ASC has a negative Return on Equity (-314.56%), as it is currently unprofitable.

Financial Health

How is Ascendis Health's financial position?

Financial Position Analysis

Short Term Liabilities: ASC's short term assets (ZAR9.8B) do not cover its short term liabilities (ZAR9.9B).

Long Term Liabilities: ASC's short term assets (ZAR9.8B) exceed its long term liabilities (ZAR250.3M).

Debt to Equity History and Analysis

Debt Level: ASC's debt to equity ratio (1322.1%) is considered high.

Reducing Debt: ASC's debt to equity ratio has increased from 67.4% to 1322.1% over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable ASC has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: ASC is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 30.4% per year.


What is Ascendis Health current dividend yield, its reliability and sustainability?

Dividend Yield vs Market

Notable Dividend: Unable to evaluate ASC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ASC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ASC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ASC's dividend payments have been increasing.

Current Payout to Shareholders

Dividend Coverage: ASC is not paying a notable dividend for the ZA market.

Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ASC's dividend in 3 years as they are not forecast to pay a notable one for the ZA market.

Next Steps


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Mark James Van Sardi (52 yo)





Mr. Mark James Van Lill Sardi, CA (SA) is Chief Executive Officer and an Executive Director at Ascendis Health Limited since October 14, 2019. Mr. Sardi served as Joint Deputy Chief Executive of Cipla Medp...

CEO Compensation Analysis

Compensation vs Market: Mark James Van's total compensation ($USD759.01K) is above average for companies of similar size in the ZA market ($USD278.61K).

Compensation vs Earnings: Mark James Van's compensation has increased whilst the company is unprofitable.

Leadership Team

Experienced Management: ASC's management team is considered experienced (2.4 years average tenure).

Board Members

Experienced Board: ASC's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Company Information

Ascendis Health Limited's employee growth, exchange listings and data sources

Key Information

  • Name: Ascendis Health Limited
  • Ticker: ASC
  • Exchange: JSE
  • Founded: 2008
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: R512.459m
  • Shares outstanding: 483.45m
  • Website:


  • Ascendis Health Limited
  • 31 Georgian Crescent East
  • Bryanston
  • Johannesburg
  • Gauteng
  • 2191
  • South Africa


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/25 21:42
End of Day Share Price2021/10/25 00:00
Annual Earnings2021/06/30

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.